Federal Trade Commission v. Watson Pharmaceuticals Inc., 677 F.3d 1298, 102 USPQ2d 1561 (11th Cir. 2012) (80 PTD, 4/26/12).The question presented by the FTC's petition for writ of certiorari is:Whether reverse-payment agreements are per se lawful unless the underlying patent litigation was a sham or the patent was obtained by fraud (as the court below held), or instead are presumptively anticompet